Goodpath

Goodpath is a virtual care provider that treats multiple chronic conditions within a single program rather than as separate point solutions. Its programs span obesity and weight management, cardiometabolic health, GLP-1 care and prescribing, musculoskeletal (MSK) and back, neck or joint pain, sleep and insomnia, digestive health including IBS/IBD, mental health, diabetes, and cancer survivorship. Care pathways are designed by a multidisciplinary physician team spanning more than 20 specialties, including endocrinology, obesity medicine, cardiology, physical therapy, pain management and clinical psychology.

Members complete a health assessment and receive a personalized, evidence-based care plan approved by the medical team. Delivery combines telehealth visits with licensed clinicians, unlimited 1:1 support from clinical health coaches holding advanced clinical degrees, psychologist-led cognitive behavioral therapy and other therapy, a mobile app for program access and progress tracking, and physical care kits containing medications, supplements, devices and resources shipped to members' homes. For weight management, Goodpath offers integrated prescribing of brand-name GLP-1s, including a direct-to-employer pricing offering ("WeightRx: Total Support") and a self-pay route through the LillyDirect pharmacy provider GiftHealth, positioning the medication within broader whole-person care for comorbidities such as pain, sleep problems and depression.

The company frames its clinical approach as integrative medicine — combining conventional medical care with evidence-based lifestyle approaches, practitioner collaboration and mind-body support — and states that its model was built to be the first scalable version of integrative care. Clinical leadership includes Akl Fahed (MD, MPH), a cardiologist at Massachusetts General Hospital and Harvard Medical School faculty member and company co-founder, and Nishant "Nishu" Uppal (MD, MBA), medical director and a practicing internal medicine physician and health policy researcher. Bill Gianoukos is CEO and co-founder.

Founding story

Goodpath was co-founded by CEO Bill Gianoukos and Dr. Akl Fahed, a cardiologist at Massachusetts General Hospital and Harvard Medical School faculty member. According to the founders, the company was created to address fragmentation in chronic care by taking an integrative care model traditionally available only to high-net-worth individuals and making it affordable and scalable through technology and AI.

Business model

Goodpath sells to employers, benefits partners and insurers, which make the service available to their employees or members as a health benefit; individuals access it through their employer or carrier rather than purchasing directly. The company positions its value proposition around reduced total cost of care for self-insured employers, and is also pursuing payer partnerships. It additionally offers direct-to-employer GLP-1 pricing and a self-pay medication option through a pharmacy partner.

Employer- and carrier-sponsored benefit contracts, complemented by direct-to-employer GLP-1 medication pricing and a self-pay GLP-1 option.

Traction

The company reports enrollment of 15-20% of eligible populations (over 20% in some materials) and 18% average enrollment in manufacturing workforces. An independent actuarial review validated its claims analysis showing a 32% reduction in employer medical costs, and the company cites average medical claims savings of about $1,900 per member across total cost of care. Its platform is described as adopted across Fortune 500 employers, benefits partners and insurers. The consumer app holds a 4.9 rating from 40 ratings on the US App Store.

Latest developments

Following the September 2025 Series A, Goodpath said it would expand into new condition categories, advance its AI personalization and outcome-prediction models, and invest in pharmacy infrastructure for GLP-1 access. Recent announcements include a transparent obesity-medication offering involving Lilly, a self-pay GLP-1 option via LillyDirect pharmacy provider GiftHealth for Zepbound, direct-to-employer and self-pay access to Wegovy through a Novo Nordisk collaboration, an expanded weight management program with GLP-1 cost and clinical-oversight controls, an expanded partnership with Sun Life U.S., a Munich Re partnership in Asia, and publication of a 2026 GLP-1 employer survey.